The following stories appear in full on today's Vidyya Medical News Service Web site.
Vidyya has kept an eye on the Ebola outbreak in Uganda since its onset was confirmed in mid October of this year. Now, the disease has claimed one of the physicians who has been instrumental in slowing the spread of the disease and treating those infected. The death from Ebola of Dr. Matthew Lukwiya, Medical
Superintendent of Lacor Hospital, Gulu District, was announced yesterday by the Uganda Ministry of Health.
For more information: Ebola Update: Ebola Claims The Life Of A Man Who Led The Fight Against It
The potential link between common childhood infections and lifelong neuropsychiatric disorders is among the most tantalizing and clinically relevant concepts in modern neuroscience. This link may be most relevant in the group of disorders collectively described as "PANDAS" (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus"). Lately, public awareness of this potential link has outpaced the scientific knowledge base, with magazines, newspaper articles and Internet chat rooms carrying this issue into the public's attention. Unfortunately, there is a particular shortage of studies of basic cellular and immune mechanisms underlying PANDAS. Read a National Institute of Mental Health Research Roundtable regarding the problems and pitfalls of the PANDAS diagnosis in today's issue.
For more information: Research Roundtable: Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus (PANDAS)
The CDC has developed an easy-to-use information sheet to assist health professionals in the set up of a mass vaccination program. The handout provides a quick framework for getting a successful program up and running and for keep patients happy.
For more information: CDC's Best Practices: Mass Influenza Vaccination Campaigns
A birth control method that's been available for 10 years in Europe and used by approximately two million women is now cleared for use in the U.S. - The Food and Drug Administration just approved Mirena, which will be available in the first quarter of 2001. In addition to being a cheap, effective form of birth-control, Mirena has been found to reduce the uterine side effects associated with Tamoxifen.
For more information: FDA Approves Contraceptive For Use In US: Mirena (Levonorgestrel-Releasing Intrauterine System) Will Be Available In First Quarter 2001
A study that shows the drug peginterferon alfa-2a, also referred to as Pegasys, is superior to other forms of interferon in the treatment of patients with chronic hepatitis C appears in the 7 December 2000 issue of the New England Journal of Medicine. Interferon, alone or in combination with an anti-viral drug, is the only effective therapy for hepatitis C. The study involved 271 patients and 22 U.S., Canadian and Australian medical centers.
For more information: Advances In The Treatment Of Hepatitis C
Today's Vidyya articles are:
As always, we hope you enjoy the issue.